Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M538Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-50.1EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)17.6Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book4.410-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.3PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M5,096,503ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with BBH

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

BBH is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

BBH: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BEST, SIMON GEOFFREYDirector 2016-10-07Buy2,750$2.933504.1view
Camilli, Kathleen MaryDirector 2016-10-07Buy5,000$4.992016.23view
Breault, Robert PaulDirector 2016-10-07Sell68,500$0.7114773.24view
Meade, Harlan DonnleyDirector, Senior Officer 2016-10-07Buy3,000$0.1665900view
Lemasson, ClaudeDirector, Senior Officer 2016-10-07Buy100,000$0.813100view
ESTEPA, JORGEDirector or Senior Officer of 10% Security Holder, 2016-10-07Buy3,500$0.426300view
Griffiths, Richard Ian10% Security Holder 2016-10-07Buy89,500$026300view
Hinchcliffe, Robert10% Security Holder, Director, Senior Officer 2016-10-07Buy3,500$0.4423900view
Reeson, DouglasDirector, Senior Officer 2016-10-07Buy15,000$0.08131900view
Anderson, Christopher RossDirector 2016-10-07Buy28,000$0.1475328.57view

Quarterly/Annual Reports about BBH:

    News about BBH:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech Oct 20 2016
    ETFs to Play as Biotech Juggles Election & Earnings Oct 17 2016
    Bank and Biotech: 2 ETFs to Watch on Outsized Volume Oct 13 2016
    Illumina's Pain Infects Biotech ETFs Oct 11 2016
    How Could Robo-Advisors Change Investing? Oct 05 2016
    Innovation In Focus For European ETFs Oct 05 2016
    VanEck to Ring The Nasdaq Stock Market Opening Bell Sep 12 2016
    Politic-proofing your portfolio: Pro Sep 09 2016
    Clinton's Proposal To Combat Drug Price Hikes Sep 02 2016
    How Analysts See United Therapeutics’ Continued Performance Sep 01 2016
    Biotech ETF Industry Outlook Aug 31 2016
    What Are Analysts’ Recommendations for Regeneron in 2016? Aug 31 2016
    Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns Aug 31 2016
    Pfizer’s Medivation Acquisition: What You Need to Know Aug 23 2016
    Ozanimod May Prove to Be a Strong Growth Driver for Celgene Aug 18 2016
    These Concerns Affected Gilead’s Change in Full-Year Guidance Aug 02 2016
    Vertex’s Orkambi to Treat Cystic Fibrosis Drives Company’s Growth Aug 01 2016
    BioMarin: Why So Many ‘Buy’ Recommendations? Jul 31 2016
    Why Did Alnylam Pharmaceuticals’s Valuation Multiples Drop in 2016? Jul 08 2016
    Understanding the Valuation Catalysts for BioMarin in 4Q16 Jul 06 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)